Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Bayer AG and AskBio Inc are conducting a Phase 2 study titled A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson’s Disease. The study aims to assess the safety and efficacy of AAV2-GDNF gene therapy in patients with moderate Parkinson’s Disease, a significant step in addressing this debilitating condition.
Intervention/Treatment: The study tests AAV2-GDNF, a gene therapy administered through bilateral image-guided infusion into the putamen, compared against a sham surgery control group. This intervention seeks to improve motor function and slow disease progression.
Study Design: This interventional study is randomized and follows a parallel assignment model. It employs quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose is treatment-focused.
Study Timeline: The study began on June 11, 2024, with primary completion expected in the future. The latest update was submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
Market Implications: This study’s progress could significantly impact Bayer’s stock performance and investor sentiment, especially if the results are positive. Success in this trial could position Bayer and AskBio as leaders in Parkinson’s treatment, potentially influencing the competitive landscape in the biotech industry.
The study is ongoing, with further details available on the ClinicalTrials portal.